The New York Times Reveals The
New Medical Marijuana Research Policy
Is Just A Stalling Tactic That Will Do Nothing To Help Patients,
While The Washington Post Reveals That Frankly It Doesnt Give A Damn.
One and A Fraction Articles
(Marijuananews note: There are two lessons here,
the subject and the reporting on it. This is the kind of comparison that is possible only
on the Internet.The Times article is excellent. The reporter clearly understands the
issue.
Both the Drug Czars statement and the "Announcement Of The Department Of Health
And Human Services Guidance On Procedures For The Provision Of Marijuana For Medical
Research" make clear that there is absolutely no intention of doing anything to help
patients.
See
HHS
Announcement On New Medical Marijuana Research Rules
Shows It Is The Same Old Game.
and
Drug Czar
Issues Statement On Marijuana For Medical Research:
"Such uses must only be part of clinical studies to expand the body of scientific
understanding."
Helping the Patients Does Not Enter Into It.
Once again the contrast between the New York Times' and Washington Posts coverage
of the medical marijuana issue demonstrates that the Post is a pathetic prohibitionist rag
that doesnt know how to cover any deviation from the party line.)
See
Washington Post and
New York Times on IOM Medical Marijuana
Compare and Contrast A Split In The Establishment?
The Drug Czars Quote In The Post Wins The Prize.
US EASES CURB ON MEDICAL MARIJUANA RESEARCH
May 22, 1999
From The New York Times
letters@nytimes.com
http://www.nytimes.com/
http://www10.nytimes.com/comment/
By SHERYL GAY STOLBERG
WASHINGTONDespite intense interest in the medical benefits of marijuana, few
scientists are studying it, because the government has always required that such work be
paid for by scarce grant money from the National Institutes of Health.
That changed Friday when the Clinton administration eased the requirement, announcing
that it would sell government-grown marijuana to privately-funded scientists.
The decision was issued as a regulation by the National Institute on Drug Abuse and is
supported by General Barry McCaffrey, who as director of the Office of National Drug
Control Policy has been the administrations most ardent opponent of the legalization
of medical marijuana. "Before, the problem was if you wanted marijuana, you had to
not only show that it was high-quality research, you had to show that it was more
important than other competing applications for NIH funding," said Chuck Blanchard,
chief counsel for McCaffreys office. "Now, as long as you are willing to show
that it is high-quality research and also provide your own funding, you can have access to
medical marijuana."
Under the ruling, marijuana studies will still be reviewed for
their scientific merit, but it will become easier for state and local governments to
pay for the research.
Experts and government officials hope the studies could some day lead to the
development of a new delivery system for marijuana, such as an inhaler, that would enable
patients to benefit from its active ingredients without suffering the toxic effects of the
smoke. Some officials already say they hope to take advantage of the new rule. "This news today gives us great hope," said Mike Nevin, a member
of the San Mateo County Board of Supervisors. About a year ago, he said, his board
allocated $500,000 for studies of marijuana in cancer and AIDS patients. "We are
hoping the federal government will grant us the ability to do this study," he said,
"and we are willing to pay."
(Marijuananews note: The involvement of state and local governments is going to be a
real problem for the feds to stall. They can play games with individual scientists, but
when they stall state and local governments, the politicians know how to embarrass the
feds into acting.)
For years, the National Institute on Drug Abuse has paid a farmer at the University of
Mississippi to grow marijuana for research, primarily studies on addiction. The government
also provides the drug to eight patients under a "compassionate use" program
authorized by the Food and Drug Administration, but that program has been closed to new
participants since 1992. In recent years, as interest grew in using marijuana as a
medicine, scientists have tried, with limited success, to persuade the National Institutes
of Health to pay for the studies. Only three studies have been
approved so far; among them is one being conducted by Dr. Donald Abrams of the University
of California at San Francisco, who said it took him five years to obtain approval to
study marijuana in AIDS patients. And even then, Abrams had to mask his true research
interest; although he wanted to examine the effects of marijuana on the weight loss
associated with AIDS, he pitched the study as one that would look at the potentially toxic
interactions between marijuana and standard AIDS medications. "We designed a study
that would appeal to the group of people funding the grant," he said.
See
Government Health
Officials Deny Marijuana and Pain Study, Again -- NORML Press Release
Fridays decision comes two months after an exhaustive study
by the Institute of Medicine, a branch of the National Academy of Sciences,
concluded that the active ingredients in marijuana, called cannabinoids, appear useful for
treating pain, nausea and the severe weight loss associated with AIDS. Two years ago, a
review by NIH officials reached a similar conclusion.
"We have had several pretty distinguished groups now say
that cannabinoids, not smoked marijuana, may have some real potential medical
usage," said Dr. Steven Gust, special assistant to the director of the National
Institute on Drug Abuse. "This is a first step towards ultimately developing
purified forms of cannabinoids that may be FDA-approvable."
(Marijuananews note: In other words, it is business as ususual.)
So far, there is only one cannabinoid-based drug on the market, Marinol, manufactured
by Unimed Pharmaceuticals Inc. of Buffalo Grove, Ill. But some patients complain that the
Marinol pills are too potent, leading researchers to theorize that an inhaler, similar to
those used by asthma patients, might be a more effective form of treatment.
See
Perhaps
The Single Most Damning Article On Medical Marijuana Fiasco I Have Ever Read
Without Intending To Be
Recognizing that such a method might take years to develop, the Institute of Medicine
report recommended that patients who did not respond to other therapy be permitted to
smoke marijuana. But the regulation issued Friday said the government does not intend to
approve "single-patient requests for marijuana," because they do not
"produce use useful scientific information."
(Marijuananews note: This ignores one of the key points of the
IOM report. From The IOM Executive Summary:
"Until a non-smoked, rapid-onset cannabinoid drug delivery system becomes
available, we acknowledge that there is no clear alternative for people suffering from
chronic conditions that might be relieved by smoking marijuana, such as pain or AIDS
wasting.
One possible approach is to treat patients as n-of-1 clinical trials, in which
patients are fully informed of their status as experimental subjects using a harmful drug
delivery system, and in which their condition is closely monitored and documented under
medical supervision, thereby increasing the knowledge base of the risks and benefits of
marijuana use under such conditions.")
Advocates for legalizing marijuana as medicine had both praise and criticism for
Fridays decision. "It is a tiny step forward, but far too tiny," said
Ethan Nadelmann, director of the Lindesmith Center, which backed initiatives in California
and Arizona to make marijuana legal for medical use. "Its
an implicit acknowledgement that the government has blocked research into medical
marijuana for explicitly political reasons for the last two decades."
Copyright: 1999 The New York Times Company
And From The Washington Post
http://www.washingtonpost.com
WASHINGTON IN BRIEF
Compiled from reports by the Associated Press, Reuters and staff
writers Stephen Barr and Juliet Eilperin
May 22, 1999; Page A09
Marijuana Research Rules Loosened
Responding to pressure from scientists and voters, the Clinton administration loosened
restraints yesterday on medical marijuana research. The move is expected to prompt more
studies to see whether the drug helps people with AIDS, cancer or eye disease.
Scientists with private grants will be able to get legal marijuana from the
governments supplygrown on a small plot in Mississippi to make sure its
all the same strength. Previously, only scientists who had won federal grants had access
to that marijuana. And only a few such federal studies have been approved.
© Copyright 1999 The Associated Press
See
Tale of Two Capital
City Newspapers:
The Washington Post and The Ottawa Citizen On Medical Marijuana
-- Maybe We Should Apologize To King George.
and
McCaffrey Named New
Editor-In-Chief of the Washington Post Exclusive To Marijuananews
and
How The Washington
Post Tells Its Readers
About The House of Lords Report On Medical Marijuana -- With Great Subtlety!
|